The role of nitric oxide in inflammation and immunity

Arthritis and Rheumatism

Volumn 41, Issue 7, 1998, Pages 1141-1151

  Clancy, Robert M ^a   Amin, Ashok R ^a   Abramson, Steven B ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; AURANOFIN; CYTOKINE; ENDOTHELIUM DERIVED RELAXING FACTOR; INDOMETACIN; METHOTREXATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXYNITRITE; SALICYLATE SODIUM;

ARTHRITIS; AUTOIMMUNE DISEASE; BLOOD VESSEL TONE; DRUG DESIGN; HOST RESISTANCE; HUMAN; INFLAMMATION; MOUSE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VASCULAR ENDOTHELIUM;

ANIMALS; HUMANS; IMMUNITY; INFLAMMATION; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RHEUMATIC DISEASES;

EID: 0031809547     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199807)41:7<1141::AID-ART2>3.0.CO;2-S     Document Type: Review

References (116)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
2. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
3. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9.
4. Christopherson KS, Bredt DS. Perspective series: nitric oxide and nitric oxide synthases. Nitric oxide in excitable tissues: physiologic roles and disease. J Clin Invest 1997;100:2424-9.
5. Clancy RM, Abramson SB. Nitric oxide: a novel mediator of inflammation. Soc Exp Biol Med 1995;210:93-101.
6. Amin AR, di Cesare PE, Vyas P, Attur M, Tzeng E, Billiar TR, et al. The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: evidence for up-regulated neuronal nitric oxide synthase. J Exp Med 1995;182: 2097-102.
7. St. Clair EW, Wilkinson WE, Lang T, Sanders L, Misukonis MA, Gilkeson GS, et al. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatic arthritis patients. J Exp Med 1996;184:1173-8.
8. Weyand CM, Wagner AD, Bjornsson J, Goronzy JJ. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996;98:1642-9.
9. Konttinen YT, Platts LAM, Tuominen S, Eklund KK, Santavirta N, Törnwall J, et al. Role of nitric oxide in Sjögren's syndrome. Arthritis Rheum 1997;40:875-83.
10. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991;351: 714-8.
11. Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992;256:225-8.
12. Lamas S, Mardsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci U S A 1992;89:6348-52.
13. Janssens SP, Shimouchi A, Quertermous T, Bloch DB, Bloch KD. Cloning and expression of a cDNA encoding human endothelium derived relaxing factor/nitric oxide synthase. J Biol Chem 1992;267:14519-22.
14. Lyons CR, Orloff GJ, Cunningham JM. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J Biol Chem 1992;267:6370-4.
15. Nathan C. Perspectives series: nitric oxide and nitric oxide synthases. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997;100:2417-23.
16. Crane BR, Arvai AS, Gachhui R, Wu C, Ghosh DK, Getzoff ED, et al. The structure of nitric oxide synthase oxygenase domain and inhibitor complexes. Science 1997;278:425-31.
17. Billiar TR. Nitric oxide: novel biology with clinical relevance. Ann Surg 1995;221:339-49.
18. Togashi H, Sasaki M, Frohman E, Taira E, Ratan RR, Dawson TM, et al. Neuronal (type 1) nitric oxide synthase regulates nuclear factor KB activity and immunologic (type II) nitric oxide synthase expression. Proc Natl Acad Sci U S A 1997;94;2676-80.
19. Bredt DS, Glatt CE, Hwang PM, Fotuhi M, Dawson TM, Snyder SH. Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron 1991;7:615-24.
20. Farrell AJ, Blake DR. Nitric oxide. Ann Rheum Dis 1996;55:7-20.
21. Gorbunov N, Esposito E. Nitric oxide as a mediator of inflammation. Int J Immunopathol Pharmacol 1993;6:67-75.
22. Belmont HM, Levartovsky D, Goel A, Amin A, Giorno R, Rediske J, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:1810-6.
23. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A 1990;87:10043-7.
24. Anstey NM, Weinberg JB, Hassanali MY, Mwaikambo ED, Manyenga D, Misukonis MA, et al. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med 1996;184:557-67.
25. Sharara AI, Perkins DJ, Misukonis MA, Chan SU, Dominitz JA, Weinberg JB. Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo. J Exp Med 1997;186:1495-502.
26. Marletta MA. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994;78:927-30.
27. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992;258:1898-902.
28. Ignarro LJ, Degnan JN, Baricos WH, Kadowitz PJ, Wolin MS. Activation of purified guanylate cyclase by nitric oxide requires heme: comparison of heme-deficient, heme reconstituted, and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta 1982;718:49-55.
29. Waldman SA, Murad F. Biochemical mechanisms underlying vascular smooth muscle relaxation: the guanylate cyclase-cyclic GMP system. J Cardiovasc Pharmacol 1988;12:S115-8.
30. Clancy RM, Abramson SB. Novel synthesis of S-nitrosoglutathione and degradation by human neutrophils. Anal Biochem 1992;204:365-71.
31. Myers PR, Minor RL Jr, Guerra R Jr, Bates JN, Harrison DG. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 1990;345:161-3.
32. Gow A, Buerk DG. Ischiropoulos H. A novel reaction mechanism for the formation of S-nitrosothiol in vivo. J Biol Chem 1997;272:2841-5.
33. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A 1992;89:7674-7.
34. Clancy RM, Levartovsky D, Leszczynska-Piziak J, Yegudin J, Abramson SB. Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S-nitrosoglutathione as a bioactive intermediary. Proc Natl Acad Sci U S A 1994;91:3680-4.
35. Jia L, Bonaventura C, Bonaventura J, Stamler JS. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996;380:221-6.
36. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 1995;268:L-699-722.
37. Goldstein S, Squadrito GL, Pryor WA, Czapski G. Direct and indirect oxidations by peroxynitrite, neither involving the hydroxyl radical. Free Radie Biol Med 1996;21:965-74.
38. Hausladen A, Privalle CT, Keng T, DeAngelo J, Stamler JS. Nitrosative stress: activation of the transcription factor OxyR. Cell 1996;86:719-29.
39. ras. J Biol Chem 1995;270:7017-20.
40. Clancy RM, Leszczynska-Piziak J, Abramson SB. Nitric oxide stimulates the ADP-ribosylation of actin in human neutrophils. Biochem Biophys Res Commun 1993;191:847-52.
41. Clancy R, Leszczynska J, Amin A, Levartovsky D, Abramson SB. Nitric oxide stimulates ADP ribosylation of actin in association with the inhibition of actin polymerization in human neutrophils. J Leukoc Biol 1995;58:196-202.
42. Frenkel SR, Clancy RM, Ricci JL, di Cesare PE, Rediske JJ, Abramson SB. Effects of nitric oxide on chondrocyte migration, adhesion, and cytoskeletal assembly. Arthritis Rheum 1996;39: 1905-12.
43. Clancy R, Rediske J, Tang X, Nijher N, Frenkel S, Philips M, et al. Outside-in signaling in the chondrocyte: nitric oxide disrupts fibronectin-induced assembly of a subplasmalemmal actin/Rho A/focal adhesion kinase signaling complex. J Clin Invest 1997; 100:1789-96.
44. Hutcheson AR, Whittle BJR, Boughton-Smith NK. Role of nitric oxide in maintaining vascular integrity in endotoxin-induced acute intestinal damage in the rat. Br J Pharmacol 1990;1282: 7889-91.
45. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991;338:1557-8.
46. Fang FC. Perspective series: first host/pathogen interactions. Mechanisms of nitric oxide related antimicrobial activity. J Clin Invest 1997;99:2818-25.
47. Middleton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993;341:465-6.
48. Kolb-Bachofen V, Fehsel K, Michel G, Ruzicka T. Epidermal keratinocyte expression of inducible nitric oxide synthase in skin lesions of psoriasis vulgaris. Lancet 1996;344:139.
49. McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie QW, Nathan CF, et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 1993;178:749-54.
50. Parkinson JF, Mitrovic B, Merrill JE. The role of nitric oxide in multiple sclerosis. J Mol Med 1997;75:174-86.
51. Kolb H, Kolb-Bachofen V. Type 1 (insulin-dependent) diabetes mellitus and nitric oxide. Diabetologia 1992;35:796-7.
52. Weinberg JB, Granger DL, Pisetsky DS, Seldin MF, Misukonis MA, Mason SN, et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med 1994;179:651-60.
53. Oates JC, Ruiz P, Alexander A, Pippen AM, Gilkeson GS. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol 1997;83:86-92.
54. Stefanovic-Racic M, Stadler J, Evans CH. Nitric oxide and arthritis. Arthritis Rheum 1993;36:1036-44.
55. Ialenti A, Moncada S, DiRosa M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br J Pharmacol 1993;110: 701-6.
56. Pelletier J-P, Jovanovic D, Fernandes JC, Geng C, Manning P, Connor JR, et al. Selective inhibition of nitric oxide synthase reduces in vivo the progression of experimental osteoarthritic lesions and production of metalloproteases and interleukin-1 [abstract]. Arthritis Rheum 1997;40 Suppl 9:S173.
57. Efron DT, Kirk SJ, Regan MC, Wasserkrug H, Barbul A. Nitric oxide generation from L-arginine is required for optimal human peripheral blood lymphocyte DNA synthesis. Surgery 1991;110: 327-34.
58. Mills CD. Molecular basis of "suppressor" macrophages: arginme metabolism via the nitric oxide synthetase pathway. J Immunol 1991;146:2719-23.
59. Merryman PF, Clancy RM, He XY, Abramson SB. Modulation of human T cell responses by nitric oxide and its derivative, S-nitrosoglutathione. Arthritis Rheum 1993;36:1414-22.
60. Chang RH, Feng MH, Liu WH, Lai MZ. Nitric oxide increased interleukin-4 expression in T lymphocytes. Immunology 1997;90: 364-9.
61. Bauer H, Jung T, Tsikas D, Stichtenoth DO, Frolich JC, Neumann C. Nitric oxide inhibits the secretion of T-helper 1-and T-helper 2-associated cytokines in activated human T cells. Immunology 1997;90:205-11.
62. Blanco FJ, Ochs RL, Schwarz H, Lotz M. Chondrocyte apoptosis induced by nitric oxide. Am J Pathol 1995;146:75-85.
63. Kitajima I, Kawahara K, Nakajima T, Soejima Y, Matsuyama T, Maruyama I. Nitric oxide-mediated apoptosis in murine mastocvtoma. Biochem Biophys Res Comm 1994;204:244-51.
64. Ankarcrona M, Dypbukt JM, Brune B, Nicotera P. Interleukin-1 beta-induced nitric oxide production activates apoptosis in pancratic RINm5F cells. Exp Cell Res 1994;213:172-7
65. Fehsel K, Kroncke KD, Meyer KL, Huber H, Wahn V, Kolb-Bachofen V. Nitric oxide induces apoptosis in mouse thymocytes. J Immunol 1995;155:2858-65.
66. Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 1997; 150:5080-5.
67. Clancy R, Abramson SB, Kohne C, Rediske J. Nitric oxide attenuates cellular hexose monophosphate shunt response to oxidants in articular chondrocytes and acts to promote oxidant injury. J Cell Physiol 1997;172:183-91.
68. Melkova Z, Lee SB, Rodriguez D, Esteban M. Bcl-2 prevents nitric oxide-mediated apoptosis and poly(ADP-ribose) polymerase cleavage. FEBS Lett 1997;403:273-8.
69. Kim Y-M, Talanian RV, Billiar R. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 1997;272:31138-48.
70. Nathan C, Hibbs JB. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 1991;3:65-70.
71. Hibbs JB, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Comm 1988;157:87-94.
72. Mulligan MS, Hevel JM, Marletta MA, Ward PA. Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A 1991;88:6338-42.
73. Oruvic A, Hearn S, Lala PK. The role of nitric oxide synthase expression in the pathogenesis of capillary leak syndrome resulting from interleukin-2 in mice. Lab Invest 1997;76:53-65.
74. Kubes PM, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991;88:4651-5.
75. Bouchier-Hayes D, Abdih H, Kelly CJ, Barry M, Redmond HP, Burke P, et al. Nitric oxide attenuates interleukin 2-induced lung injury. Br J Surg 1997;84:540-2.
76. Salvemini D, Masferrer JL. Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo, and in vivo studies. Methods Enzymol 1996;269:12-25.
77. Swierkosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol 1995;114:1335-42.
78. Habib A, Bernard C, Kebret M, Creminon C, Esposito B, Tedgui A, et al. Regulation of the expression of cyclooxygenase-2 by nitric oxide in rat peritoneal macrophages. J Immunol 1997;158: 3845-51.
79. Amin AR, Attur M, Patel RJ, Thakker GD, Marshall PJ, Rediske J, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. J Clin Invest 1997;99:1231-7.
80. Clancy RM, Leszczynska-Piziak J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest 1992;90:1116-21.
81. Masini E, Pistelli A, Gambassi F, di Bello MG, Mannaioni PF. The role of nitric oxide in anaphylactic reaction of isolated guinea pig hearts and mast cells. In: Moncada S, Nishko G, editors. Nitric oxide: brain and immune system. London: Portland Press; 1996. p. 277.
82. Gutierrez HH, Nieves B, Chumley P, Rivera A, Freeman BA. Nitric oxide regulation of superoxide-dependent lung injury: oxidant-protective actions of endogenously produced and exogenously administered nitric oxide. Free Radic Biol Med 1996;21: 43-52.
83. Roissaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399-405.
84. Guidot DM, Repine MJ, Hybertson BM, Repine JE. Inhaled nitric oxide prevents neutrophil-mediated, oxygen radical-dependent leak in isolated rat lungs. Am J Physiol 1995;269:L2-5.
85. Bloomfield GL, Halloway S, Ridings PC, Fisher BJ, Blocher CR, Sholley M, et al. Pretreatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury. Crit Care Med 1997;25: 584-93.
86. Cooke JP, Tsao PS. Cytoprotective effects of nitric oxide. Circulation 1993;88:2451-5.
87. Lefer AM. Cytoprotective actions of nitric oxide donors in ischemia-reperfusion injury. In: Moncada S, Marletta MA, Higgs EA, editors. The biology of nitric oxide. London: Portland Press; 1992. p. 55.
88. Kilbourn RG, Szabo C, Traber DL. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Shock 1997;7:235-46.
89. Christopher TA, Ma X, Lefer AM. Beneficial actions of S-nitroso-N-acetyl-penicillamine, a nitric oxide donor, in murine traumatic shock. Shock 1994;1:19-24.
90. Oates J, Gilkeson GS. Increased apoptosis of MRL/LPR splenocytes is secondary to elevated nitric oxide production [abstract]. Arthritis Rheum 1997;40 Suppl 9:S258.
91. Gilkeson G, Mudgett JS, Seldin MF, Ruiz P, Alexander AA, Misukonis MA, et al. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide svnthase type 2. J Exp Med 1997;186:365-73.
92. Gilkeson G, Cannon C, Goldman D, Petri M. Correlation of a serum measure of nitric oxide production with lupus disease activity measures [abstract]. Arthritis Rheum 1996;39 Suppl 9:S251.
93. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
94. Belmont HM, Buyon J, Giorno R, Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematous: the Shwartzman phenomenon revisited. Arthritis Rheum 1994;37:376-83.
95. Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus: interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996;39:9-22.
96. Farrell AJ, Blake D, Palmer RMJ, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992;51:1219-22.
97. Sakurai H, Kohsaka H, Liu M-F, Higashiyama H, Hirata Y, Kanno K, et al. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 1995;96:2357-63.
98. Hayashi T, Abe E, Yamate T, Taguchi Y, Jasin HE. Nitric oxide production by superficial and deep articular chondrocytes. Arthritis Rheum 1997;40:261-9.
99. McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, Sturrock RD, et al. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med 1996;184: 1519-24.
100. Mayhan WG. Role of nitric oxide in leukotriene C4-induced increases in microvascular transport. Am J Physiol 1993;265: H409-14.
101. Mayhan WG. Role of nitric oxide in modulating permeability of hamster cheek pouch in response to adenosine 5′-diphosphate and bradykinin. Inflammation 1996;16:295-305.
102. Lander HM, Sehajpal P, Levine DM, Novogrodsky A. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J Immunol 1993;150:1509-16.
103. Leibovich SJ, Polverini PJ, Fong TW, Harlow LA, Koch AE. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci U S A 1994;91:4190-4.
104. Taskiran D, Stefanovic-Racic M, Georgescu H, Evans C. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Comm 1994;200:142-8.
105. Murrell GA, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995;206:15-21.
106. Pelletier J-P, Mineau F, Ranger P, Tardif G, Martel-Pelletier J. The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation [abstract]. Arthritis Rheum 1996;38 Suppl 9:S313.
107. Amin AR, Patel P, Vyas P, di Cesare PE, Attur M, Abramson SB. Nitric oxide produced by cartilage-specific nitric oxide synthase is a common mediator of cartilage degradation in both rheumatoid arthritis and osteoarthritis [abstract]. J Invest Res 1996;44:236A.
108. Maier R, Bilbe G, Rediske J, Lotz M. Inducible nitric oxide synthase from human articular chondrocytes: cDNA cloning and analysis of mRNA expression. Biochim Biophys Acta 1994;1208: 145-50.
109. Geng Y, Blanco F, Cornelison M, Lotz M. Regulation of inducible cyclooxygenase in human articular chondrocytes. J Immunol 1995;155:796-801.
110. Blanco FJ, Lotz M. UK-1 induced nitric oxide inhibits chondrocyte proliferation via PGE2. Exp Cell Res 1995;218:319-25.
111. Amin AR, Vyas P, Attur M, Leszczynska-Piziak J, Patel IR, Weissmann G, et al. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci U S A 1995;92:7926-30.
112. 2) spontaneously produced by osteoarthritis-affected cartilage regulate stromelysin (MMP-3) production [abstract]. Arthritis Rheum 1997;40 Suppl 9:S181.
113. 2 and IL-8. Proc Assoc Am Physicians 1998;110:1-8.
114. Broxmeyer HE. Is interleukin 17, an inducible cytokine that stimulates production of other cytokines, merely a redundant player in a sea of other biomolecules? J Exp Med 1997;183: 2411-5.
115. Attur MG, Patel RN, Abramson SB, Amin AR. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum 1997;40:1050-3.
116. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 1996;93: 14014-9.